ArticleTrials2011
Why we need easy access to all data from all clinical trials and how to accomplish it.
Article in Trials, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Industry sponsorship and research outcome: systematic review with meta-analysis.Intensive care medicine · 2018Pooled it
- Industry sponsorship and research outcome.The Cochrane database of systematic reviews · 2017Pooled it
- Inadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic review.Journal of clinical epidemiology · 2015Pooled it
- Best Practices for Ethical Sharing of Individual-Level Health Research Data From Low- and Middle-Income Settings.Journal of empirical research on human research ethics : JERHRE · 2015Pooled it
- Barriers to and facilitators of interventions to counter publication bias: thematic analysis of scholarly articles and stakeholder interviews.BMC health services research · 2014Pooled it
- Contacting authors to retrieve individual patient data: study protocol for a randomized controlled trial.Trials · 2016Trial
- The data transparency crisis in research: Lessons from systematic reviews and meta-analyses.PLoS medicine · 2026Article
- A Review and Future Directions for Global Public Health Security Assessment Tools.China CDC weekly · 2026Article
- A call for open science in forensics.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Clinical trial data sharing: a cross-sectional study of outcomes associated with two U.S. National Institutes of Health models.Scientific data · 2023Article
- Data sharing implementation in top 10 ophthalmology journals in 2021.BMJ open ophthalmology · 2023Article
- Clinical Trial Data Transparency in the EU: Is the New Clinical Trials Regulation a Game-Changer?IIC; international review of industrial property and copyright law · 2023Article
- Systematic review and meta-analyses of studies analysing instructions to authors from 1987 to 2017.Nature communications · 2021Article
- Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide.BMC medical research methodology · 2020Article
- Open to the public: paywalls and the public rationale for open access medical research publishing.Research involvement and engagement · 2020Article
- Clinical Trial Participants' Views of the Risks and Benefits of Data Sharing.The New England journal of medicine · 2018Article
- To share or not to share? Expected pros and cons of data sharing in radiological research.European radiology · 2018Article
- Better governance, better access: practising responsible data sharing in the METADAC governance infrastructure.Human genomics · 2018Article
- Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review.Systematic reviews · 2018Article
- Do Robotics and Virtual Reality Add Real Progress to Mirror Therapy Rehabilitation? A Scoping Review.Rehabilitation research and practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
International calls for registering all trials involving humans and for sharing the results, and sometimes also the raw data and the trial protocols, have increased in recent years. Such calls have come, for example, from the Organization for Economic Cooperation and Development (OECD), the World Health Organization (WHO), the US National Institutes of Heath, the US Congress, the European Commission, the European ombudsman, journal editors, The Cochrane Collaboration, and several funders, for example the UK Medical Research Council, the Wellcome Trust, the Bill and Melinda Gates Foundation and the Hewlett Foundation. Calls for data sharing have mostly been restricted to publicly-funded research, but I argue that the distinction between publicly-funded and industry-funded research is an artificial and irrelevant one, as the interests of the patients must override commercial interests. I also argue why it is a moral imperative to render all results from all trials involving humans, also healthy volunteers, publicly available. Respect for trial participants who often run a personal and unknown risk by participating in trials requires that they--and therefore also the society at large that they represent--be seen as the ultimate owners of trial data. Data sharing would lead to tremendous benefits for patients, progress in science, and rational use of healthcare resources based on evidence we can trust. The harmful consequences are minor compared to the benefits. It has been amply documented that the current situation, with selective reporting of favorable research and biased data analyses being the norm rather than the exception, is harmful to patients and has led to the death of tens of thousands of patients that could have been avoided. National and supranational legislation is needed to make data sharing happen as guidelines and other voluntary agreements do not work. I propose the contents of such legislation and of appropriate sanctions to hold accountable those who refuse to share their data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.